Abstract
Transsexualism refers to individuals that identify themselves as members of the opposite gender and who strive to acquire the physical appearance and psychosocial role compatible with that gender. Gender reassignment therapy is applied through hormonal treatment ± surgical intervention in addition to psychological support. Hormone treatment for male-to-female transsexuals includes estrogen supplementation ± suppression of androgen secretion or action. Sex hormones are important determinants of the metabolic profile. The impact on cardiovascular disease appears to be gender-related but overall evidence remains conflicting. Gender reassignment therapy has been associated with elevated triglyceride concentrations, often accompanied by an increase in high density lipoprotein levels, reduced circulating homocysteine (Hcy), uric acid and creatinine levels as well as an adverse effect on glycemic control. Markers of inflammation, oxidative stress and endothelial function are also affected in various ways, while alterations in hemostatic and fibrinolytic factors favor thrombosis (arterial and/or venous). Male-to-female transsexuals may be adversely affected by both estrogen administration and androgen deprivation, as reported in prostate cancer. Therefore, vascular risk factor screening and potential intervention may be required prior to and during gender reassignment therapy (both hormone and surgical).
Keywords: Male-to-female transsexuals, transsexuals, cardiovascular, estrogen, antiandrogen, gender reassignment therapy, Transsexualism, EE, E2, transdermal, HRT, cyproter-one acetate (CA), flutamide, nilutamide, non-steroidal antiandrogens, spironolactone, diuretic, antiandro-genic, long-acting gonadotropin, finasteride, MetS, type 2 diabetes mellitus (DM), homocysteine, hemostatic, fibrinolytic, vascular function, Estrogen treatment, M-value, FIBRINOLYTIC FACTORS, RENAL FUNCTION, Creatinine, Homocysteine (Hcy), Uric Acid, ADIPOKINES, creatinine values, interleukin-6, superoxide dismutase, glutathione (GSH), asymmetric dimethylarginine, Tumor necrosis factor (TNF), sex hormone binding globulin
Current Pharmaceutical Design
Title: The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Volume: 16 Issue: 34
Author(s): Eirini Lioudaki, Emmanuel S. Ganotakis, Dimitri P. Mikhailidis and Devaki R. Nair
Affiliation:
Keywords: Male-to-female transsexuals, transsexuals, cardiovascular, estrogen, antiandrogen, gender reassignment therapy, Transsexualism, EE, E2, transdermal, HRT, cyproter-one acetate (CA), flutamide, nilutamide, non-steroidal antiandrogens, spironolactone, diuretic, antiandro-genic, long-acting gonadotropin, finasteride, MetS, type 2 diabetes mellitus (DM), homocysteine, hemostatic, fibrinolytic, vascular function, Estrogen treatment, M-value, FIBRINOLYTIC FACTORS, RENAL FUNCTION, Creatinine, Homocysteine (Hcy), Uric Acid, ADIPOKINES, creatinine values, interleukin-6, superoxide dismutase, glutathione (GSH), asymmetric dimethylarginine, Tumor necrosis factor (TNF), sex hormone binding globulin
Abstract: Transsexualism refers to individuals that identify themselves as members of the opposite gender and who strive to acquire the physical appearance and psychosocial role compatible with that gender. Gender reassignment therapy is applied through hormonal treatment ± surgical intervention in addition to psychological support. Hormone treatment for male-to-female transsexuals includes estrogen supplementation ± suppression of androgen secretion or action. Sex hormones are important determinants of the metabolic profile. The impact on cardiovascular disease appears to be gender-related but overall evidence remains conflicting. Gender reassignment therapy has been associated with elevated triglyceride concentrations, often accompanied by an increase in high density lipoprotein levels, reduced circulating homocysteine (Hcy), uric acid and creatinine levels as well as an adverse effect on glycemic control. Markers of inflammation, oxidative stress and endothelial function are also affected in various ways, while alterations in hemostatic and fibrinolytic factors favor thrombosis (arterial and/or venous). Male-to-female transsexuals may be adversely affected by both estrogen administration and androgen deprivation, as reported in prostate cancer. Therefore, vascular risk factor screening and potential intervention may be required prior to and during gender reassignment therapy (both hormone and surgical).
Export Options
About this article
Cite this article as:
Lioudaki Eirini, S. Ganotakis Emmanuel, P. Mikhailidis Dimitri and R. Nair Devaki, The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals, Current Pharmaceutical Design 2010; 16 (34) . https://dx.doi.org/10.2174/138161210794455049
DOI https://dx.doi.org/10.2174/138161210794455049 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: The Bioenergetics of Cancer, the Warburg Hypothesis and the Mitochondrial Function)
Current Pharmaceutical Biotechnology Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Synthesis and Biological Evaluation of New Naphthoquinones Derivatives
Current Organic Synthesis Design of Peptide Imaging Agents for Whole-body and Intraoperative Molecular Imaging
Current Medicinal Chemistry Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Current Topics in Medicinal Chemistry Potential Health Hazards for Cumulative Exposures to Phthalates and Ionizing Radiation in High-Risk Pediatric Population
Mini-Reviews in Medicinal Chemistry Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery